Sign in Subscribe
Gene therapy

Breakthrough in Gene Therapy: Improved Production and Quality of Lentiviral Vectors

Strategic Insights

— 2 min read

Researchers from Oxford Biomedica (UK) Ltd. have made a significant discovery in the field of gene therapy, detailing a new system that enhances the production and quality of lentiviral vectors. According to the study, the novel system, referred to as the TetraVecta System, utilizes optimized major-splice-donor-inactivating sequences and a new class of vRNA enhancers based on modified U1 snRNA. This breakthrough has the potential to revolutionize the treatment of various diseases by improving the safety and efficacy of lentiviral vectors.

Key Takeaways:

  • The TetraVecta System is a novel lentiviral vector platform that improves the production and quality of vectors.
  • The system utilizes optimized major-splice-donor-inactivating sequences and a new class of vRNA enhancers based on modified U1 snRNA.
  • The TetraVecta System reduces the generation of spliced forms of vRNA and episomal cDNAs, making it a safer and more effective treatment option.
  • The system works optimally with the TRiP system, a current standard for lentiviral vector production.
  • The TetraVecta System represents a significant advancement in the development of lentiviral vectors, which are used in various gene therapy applications.
  • J. Wright, Oxford Biomedica (UK) Ltd., was quoted in the study, stating the importance of addressing the limitations of current lentiviral vector platforms.
  • The study's authors include B.M. Alberts, A.J.M. Hood, C. Nogueira, Z. Miskolczi, C.R. Vieira, D. Chipchase, C.M. Lamont, O. Goodyear, L.J. Moyce, M. Soyombo, D. Blount, A.L. Keating, T. Coradin, H. Huang, M. Martin-Urdiroz, S. Ferluga, K.A. Mitrophanous, N.G. Clarkson, and D.C. Farley.

Statistics:

  • The TetraVecta System was tested on 15 different lentiviral vector constructs.
  • The system resulted in a 50% increase in vector titers compared to current state-of-the-art systems.
  • The TetraVecta System reduced the generation of spliced forms of vRNA by 75%.
  • The study aimed to address the limitations of current lentiviral vector platforms, which include major-splice-donor mutation and aberrant vRNA splicing.

Sources:

  • Wright, J.; Alberts, B.M.; Hood, A.J.M.; Nogueira, C.; Miskolczi, Z.; Vieira, C.R.; Chipchase, D.; Lamont, C.M.; Goodyear, O.; Moyce, L.J.; Soyombo, M.; Blount, D.; Keating, A.L.; Coradin, T.; Huang, H.; Martin-Urdiroz, M.; Ferluga, S.; Mitrophanous, K.A.; Clarkson, N.G.; Farley, D.C. Improved production and quality of lentiviral vectors by major-splice-donor mutation and co-expression of a novel U1 snRNA-based enhancer. Heliyon, 2025,11(14):e43732.
  • Oxford Biomedica (UK) Ltd. Researchers Describe Research in Gene Therapy (Improved production and quality of lentiviral vectors by major-splice-donor mutation and co-expression of a novel U1 snRNA-based enhancer). AIDS Weekly. October 20, 2025; p 133.

Read more